Form 4: Puma Biotechnology Director Sells 27,000 Shares Under Pre-Arranged Plan

A director at Puma Biotechnology, Adrian Senderowicz, sold 27,000 shares of common stock for approximately $91,800 under a pre-arranged 10b5-1 trading plan.

Summary

• Adrian Senderowicz, a Director of Puma Biotechnology, Inc. (PBYI), sold 27,000 shares of the company's common stock.
• The transaction occurred on June 13, 2025.
• The shares were sold at a weighted average price of $3.40 per share, with prices ranging from $3.34 to $3.50.
• The total value of the shares sold is approximately $91,800 (27,000 shares * $3.40/share).
• The sale was executed pursuant to a Rule 10b5-1(c) trading plan, which was adopted on March 12, 2025.
• Following this transaction, Adrian Senderowicz beneficially owns 27,000 shares of Puma Biotechnology common stock directly, indicating he held 54,000 shares prior to the sale.

Sentiment

Score: 3

Explanation: The sale of shares by a director, even under a 10b5-1 plan, generally carries a negative sentiment as it reduces insider ownership and can be perceived as a lack of confidence, despite the pre-planned nature.

Positives

• The sale was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned transaction rather than an immediate reaction to new, non-public information.

Negatives

• A director selling a significant number of shares can be perceived negatively by investors, as it may suggest a lack of confidence in the company's future prospects or valuation.
• The sale represents a reduction in the director's direct ownership stake in the company.

Risks

• Increased investor scrutiny regarding insider selling, potentially leading to negative market sentiment or downward pressure on the stock price.

Future Outlook

NA

Industry Context

This Form 4 filing details an individual insider transaction and does not provide broader industry context or trends. It is specific to the trading activity of a director at Puma Biotechnology, Inc.

Stakeholder Impact

• Shareholders: May interpret the director's sale as a negative signal, potentially leading to downward pressure on the stock price due to concerns about insider confidence.

Key Dates

Recommendation

Keywords

Puma Biotechnology, PBYI, SEC Form 4, Insider Trading, Stock Sale, Director Transaction, Adrian Senderowicz, 10b5-1 Plan, Biotechnology Stock